Core Viewpoint - The joint issuance of the policy by nine departments aims to promote high-quality development in the pharmaceutical retail industry, focusing on various dimensions such as improving pharmaceutical services, innovating health services, and optimizing industry structure, which will inject strong momentum into the digital transformation of the sector [1][2] Group 1: Policy Impact - The policy mandates pharmaceutical retail enterprises to accurately collect and verify drug traceability codes during sales, enhancing drug traceability management and application, thereby improving medication safety supervision and risk control of medical insurance funds [1] - The policy emphasizes the need for digitalization and intensive transformation in the pharmaceutical retail industry, which is expected to release concentrated demand for these changes [2] Group 2: Company Positioning - Ailong Technology (688329.SH) is positioned to benefit from the policy due to its strong foundation in smart pharmacy, smart wards, smart storage, and pharmaceutical information, which allows it to fully leverage the policy dividends and open up new growth spaces [1] - The company has developed the "Drug 4π All-Dimensional Spherical Scanning System," which achieves comprehensive recognition of traceability codes and meets the upgraded traceability management needs of retail pharmacies, already receiving high recognition in practical use [1] - Ailong Technology has established a comprehensive scene system covering material management within hospitals, achieving domestic substitution of core equipment and reaching international leading technical standards, thus forming a complete product line from single products to overall solutions [2] Group 3: Market Potential - The company's full series of dispensing machines align precisely with the policy's requirements for traceability management, enabling automatic collection and association of traceability code information during prescription dispensing, thus creating a new paradigm of unmanned traceability code collection in the industry [2] - The products and services of Ailong Technology have been validated by over a thousand medical institutions, indicating significant potential for expansion in the retail sector as the policy details gradually take effect [2] - With its first-mover advantage, the company is expected to capture market share and enhance its performance growth momentum as the policy is implemented [2]

Group 1 - The core viewpoint of the news is that Ailong Technology has significantly narrowed its losses in the first half of 2025, with a net profit attributable to the parent company of -8.39 million yuan, and it aims for a full-year profit target of 19.2 million to 29 million yuan [1] - The company anticipates that revenue will gradually be recognized as projects enter the acceptance phase in the second half of the year, combined with ongoing cost-saving measures, leading to an acceleration in performance improvement [1] Group 2 - Policy changes are a significant driver for Ailong Technology's business development, particularly the implementation of drug traceability codes in the medical insurance sector starting July 1, 2025, which presents substantial opportunities in the drug traceability field [2] - Ailong Technology has developed a leading "4π full-dimensional spherical scanning system" that has been well-received by users, enabling precise identification and collection of drug traceability codes without dead angles [2] Group 3 - The company has established a comprehensive product layout in the field of smart management of medical supplies, covering four core areas: smart pharmacies, smart wards, smart warehousing, and pharmaceutical information [3] - Ailong Technology's products are currently used in over 1,200 medical institutions in China, including more than 580 top-tier hospitals, maintaining a leading market share [3] Group 4 - Ailong Technology is accelerating its global expansion as part of its dual-driven strategy of "panoramic strategy and globalization," focusing on Southeast Asia as a key overseas market [4] - The company emphasizes its strong customization capabilities to provide tailored solutions for hospitals, leveraging its experience from the domestic market [4] Group 5 - The company has integrated AI technology into pharmaceutical management, transitioning traditional models to a "data-driven" approach, injecting new momentum into hospital pharmaceutical services [5] Group 6 - Looking ahead, Ailong Technology plans to focus on the development of its core business, continuously improve its business segments, and implement its "panoramic and global" development strategy [6] - The company aims to adjust its product brand strategies based on market demand changes and enhance cost optimization and expense control through refined management [6]